<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649479</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-I/2012/FC-01</org_study_id>
    <secondary_id>2012-A00705-38</secondary_id>
    <nct_id>NCT01649479</nct_id>
  </id_info>
  <brief_title>Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome</brief_title>
  <acronym>MENT-APL-O</acronym>
  <official_title>Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to estimate the lifetime prevalence of major psychiatric&#xD;
      disorders (axis I DSM-IV; Diagnostic and Statistical Manual of Mental Disorders, version IV)&#xD;
      in a large sample of patients with developed clinical signs of pure obstetrical&#xD;
      antiphospholipid syndrome (suspected APS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:&#xD;
&#xD;
      A. To compare the lifetime prevalence of these major disorders between groups;&#xD;
&#xD;
      B. To assess the association of different, targeted, qualitative biomarkers with clinical&#xD;
      symptomatology;&#xD;
&#xD;
      C. To assess the association between the presence of &quot;transitory APS&quot; and the presence of&#xD;
      psychiatric disorders;&#xD;
&#xD;
      D. Estimate and compare the current prevalence (= the day of assessment) of major psychiatric&#xD;
      disorders in the sample of patients who developed clinical signs of obstetrical APS;&#xD;
&#xD;
      E. Estimate the current prevalence (= the day of assessment) and intensity of major&#xD;
      depressive episodes (MDE) in the sample of patients;&#xD;
&#xD;
      F. Compare the prevalence of current MDE and the intensity of depressive symptoms present&#xD;
      between groups;&#xD;
&#xD;
      G. Estimate and compare the (lifetime and current) prevalence by category of psychiatric&#xD;
      disorders (psychotic, anxiety, mood, etc..) in the APS group with that in the thrombophilic&#xD;
      group and the remaining group;&#xD;
&#xD;
      H. To study the average age of onset of psychiatric disorders and clinical manifestations of&#xD;
      APS in the sample of patients who developed clinical signs of obstetrical APS;&#xD;
&#xD;
      I. Compare the mean ages between groups;&#xD;
&#xD;
      J. Compare the mean age at onset of psychiatric disorders with the average age of the first&#xD;
      clinical manifestation of the disease in the group of women with APS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Impossible to include patients at a correct rate; patients don't want to come back so they&#xD;
    refuse participation.&#xD;
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence/absence of (lifetime) psychiatric symptoms</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>The Mini International Neuropsychiatric Interview (MINI 6) will be used to determined the presence/absence of (lifetime) psychiatric symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence/absence of (current) psychiatric symptoms</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>The Mini International Neuropsychiatric Interview (MINI 6) will be used to determined the presence/absence of (current) psychiatric symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCID-1 score</measure>
    <time_frame>baseline (transversal); Day 0 or up to Day 15</time_frame>
    <description>Structured Clinical Interview for Disorders (SCID-1) score for patients with a positive MINI evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDQ score</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>Mood Disorder Questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI score</measure>
    <time_frame>baseline (transversal); Day 0 or up to Day 15</time_frame>
    <description>The Beck Depression Inventory (BDI) score for currently depressed patients only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDS-C score</measure>
    <time_frame>baseline (transversal); Day 0 or up Day 15</time_frame>
    <description>Inventory of Depressive Symptomatology (IDS-C) for currently depressed patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of lupus anticoagulant</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of anticardiolipid antibodies</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of anti-beta2-glycoprotein 1 antibodies</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>deficit in antithrombin: yes/no</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deficit in protein C: yes/no</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deficit in protein S: yes/no</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess of FVIII: yes/no</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>Excess of coagulation factor VIII?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess of homocystein? yes/no</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of allele F5 1691A</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>F5 1691A: allele 1691A for the factor V leiden gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of allele F2 20210A</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>F2 20210A: allele 20210A for the prothrombin gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of allele JAK2 617F</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>JAK2 617F: 617f mutation at the jak2 gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at beginning of psychiatric symptoms</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>in years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at beginning of APL or thrombophilia symptoms</measure>
    <time_frame>baseline (transversal); Day 0</time_frame>
    <description>in years</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Suspected Obstetrical APS; confirmed APS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.&#xD;
Bloodwork later confirms that these patients have APS.&#xD;
All patients included in this study will have the following interventions:&#xD;
antiphospholipid antibody tests&#xD;
thrombophilia bloodwork&#xD;
psychiatric evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sus. Obst. APS, confirmed thrombophilia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.&#xD;
Bloodwork later confirms that these patients are thrombophilic.&#xD;
All patients included in this study will have the following interventions:&#xD;
antiphospholipid antibody tests&#xD;
thrombophilia bloodwork&#xD;
psychiatric evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected Obstectrical APS; unconfirmed</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.&#xD;
Bloodwork cannot confirm APS, nor thrombophilia.&#xD;
All patients included in this study will have the following interventions:&#xD;
antiphospholipid antibody tests&#xD;
thrombophilia bloodwork&#xD;
psychiatric evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antiphospholipid antibody tests</intervention_name>
    <description>Each patient will be tested for antiphospholipid antibodies.</description>
    <arm_group_label>Sus. Obst. APS, confirmed thrombophilia</arm_group_label>
    <arm_group_label>Suspected Obstectrical APS; unconfirmed</arm_group_label>
    <arm_group_label>Suspected Obstetrical APS; confirmed APS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thrombophilia bloodwork</intervention_name>
    <description>Bloodwork will be drawn up for:&#xD;
antithrombin, protein C, protein S&#xD;
Factor V Leiden polymorphisms (F5 1691A)&#xD;
prothrombin 20210A gene polymorphism (F2 20210A)&#xD;
JAK2 617F Mutation&#xD;
Homocysteine&#xD;
Factor VIII</description>
    <arm_group_label>Sus. Obst. APS, confirmed thrombophilia</arm_group_label>
    <arm_group_label>Suspected Obstectrical APS; unconfirmed</arm_group_label>
    <arm_group_label>Suspected Obstetrical APS; confirmed APS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychiatric evaluation</intervention_name>
    <description>During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).</description>
    <arm_group_label>Sus. Obst. APS, confirmed thrombophilia</arm_group_label>
    <arm_group_label>Suspected Obstectrical APS; unconfirmed</arm_group_label>
    <arm_group_label>Suspected Obstetrical APS; confirmed APS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given his/her informed and signed consent&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Not postmenopausal&#xD;
&#xD;
          -  Able to understand the nature, purpose and methodology of the study and agreed to&#xD;
             cooperate in clinical and biological assessments&#xD;
&#xD;
          -  Available for 12 weeks of follow-up&#xD;
&#xD;
          -  Isolated obstetric morbidity, defined by at least one of the following criteria:&#xD;
&#xD;
          -  at least three consecutive episodes of unexplained, early, embryonic miscarriage,&#xD;
             which occurred before the 10th week of pregnancy, with normal maternal anatomic and&#xD;
             hormonal assessment, normal karyotypes for both biological parents;&#xD;
&#xD;
          -  at least one unexplained fetal death, defined as occurring after the 10th week of&#xD;
             pregnancy, involving a morphologically normal fetus as documented by ultrasound&#xD;
             examination or direct examination of the conceptus;&#xD;
&#xD;
          -  at least one premature birth of a morphologically normal fetus before the 34th week of&#xD;
             pregnancy, because of: (1) pre-eclampsia, severe or not, according to the American&#xD;
             College of Obstetrics and Gynecology, ACOG, 2002; (2)documented placental&#xD;
             insufficiency, defined by the following parameters: (2a) abnormal or non-reassuring&#xD;
             fetal monitoring exam, in general a non-reactive absence-of-fetal-stress test (fetal&#xD;
             monitoring), suggesting fetal hypoxemia; (2b) a Doppler examination of uterine&#xD;
             arteries suggesting fetal hypoxemia, ie the absence of end-diastolic flow in the&#xD;
             umbilical arteries; (2c) oligohydramnios, that is to say, an amniotic flow index &lt;5&#xD;
             cm; (2d) indexed birth weight for gestational age and sex below the 10th percentile.&#xD;
&#xD;
          -  Patient willing to accept psychological and medical care over the long term&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is participating in another study&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  The patient is under judicial protection, under tutorship or curatorship&#xD;
&#xD;
          -  The patient refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to correctly inform the patient&#xD;
&#xD;
          -  The patient is pregnant, parturient or breastfeeding&#xD;
&#xD;
          -  Systemic vascular morbidity, defined by the following criteria: (1) Any personal&#xD;
             history of venous thromboembolism, defined by the occurrence of deep phlebitis and /&#xD;
             or a pulmonary embolism, diagnosed by means of objective exploration ; (2)Any personal&#xD;
             history of superficial venous thrombosis; (3) Any personal history of clinical,&#xD;
             symptomatic relapses of arterial insufficiency - the latter may be cerebro vascular in&#xD;
             nature (transient ischemic attack, stroke, etc..), coronary in nature (angina,&#xD;
             myocardial infarction, etc..) or otherwise (claudication mesenteric, etc.), and&#xD;
             objectively diagnosed.&#xD;
&#xD;
          -  Systemic inflammatory disease: any history of systemic disease, lupus erythematosus or&#xD;
             other connective, rheumatoid arthritis&#xD;
&#xD;
          -  Any history of neoplastic disease&#xD;
&#xD;
          -  Chronic antithrombotic treatment taken before the occurrence of obstetrical&#xD;
             complications&#xD;
&#xD;
          -  Any chronic immunosuppressive therapy or immunomodulatory therapy (eg corticosteroids,&#xD;
             hydroxochloroquine or intravenous immunoglobulins)&#xD;
&#xD;
          -  Fetal loss can be explained by infectious, metabolic (including rates of fasting blood&#xD;
             glucose&gt; 7 mmol / L), anatomical or hormonal factors&#xD;
&#xD;
          -  History of infection with hepatitis B, hepatitis C or HIV&#xD;
&#xD;
          -  Taking antipsychotic treatment potentially implicated in biological autoimmune&#xD;
             abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>APHM - Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital de la Conception</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital La Timone Adultes</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2012</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstetrical antiphospholipid syndrome</keyword>
  <keyword>Thrombophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

